Floatz logo

FLUTICASONE

Recurrent Adult Acute Myeloid Leukemia

Virginia Commonwealth UniversitySmall moleculePhase 2Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Recurrent Adult Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
ETOPOSIDE
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3BBB
Mitoxantrone
Medical College of Wisconsin
Phase 2BBB
Benadryl
M.D. Anderson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Male Breast CancerDormant
BB
Indicative ·
71 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →